Plexus Corp. (NASDAQ:PLXS) Insider Steven J. Frisch Sells 2,554 Shares

Plexus Corp. (NASDAQ:PLXS) insider Steven J. Frisch sold 2,554 shares of Plexus stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $106.12, for a total value of $271,030.48. Following the completion of the sale, the insider now directly owns 59,413 shares in the company, valued at approximately $6,304,907.56. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Plexus Stock Performance

Shares of NASDAQ PLXS traded up $0.62 during midday trading on Wednesday, hitting $107.04. 78,819 shares of the company’s stock were exchanged, compared to its average volume of 120,473. The company has a quick ratio of 0.64, a current ratio of 1.51 and a debt-to-equity ratio of 0.15. Plexus Corp. has a 12 month low of $85.35 and a 12 month high of $114.06. The company’s 50 day moving average price is $95.76 and its 200 day moving average price is $98.96. The firm has a market capitalization of $2.95 billion, a PE ratio of 29.57 and a beta of 1.00.

Plexus (NASDAQ:PLXS) last issued its earnings results on Wednesday, April 24th. The technology company reported $0.94 EPS for the quarter, topping the consensus estimate of $0.87 by $0.07. Plexus had a return on equity of 10.77% and a net margin of 2.54%. The company had revenue of $966.90 million during the quarter, compared to the consensus estimate of $950.75 million. During the same period in the previous year, the company posted $1.45 EPS. The firm’s revenue for the quarter was down 9.7% compared to the same quarter last year. As a group, analysts predict that Plexus Corp. will post 3.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Stifel Nicolaus lifted their target price on Plexus from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Friday, April 26th. TheStreet lowered Plexus from a “b” rating to a “c+” rating in a research report on Tuesday, February 13th. Benchmark reaffirmed a “buy” rating and set a $110.00 price target on shares of Plexus in a research report on Wednesday, January 17th. Needham & Company LLC boosted their price target on Plexus from $107.00 to $114.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Finally, Sidoti lowered Plexus from a “buy” rating to a “neutral” rating and set a $112.00 price target on the stock. in a research report on Tuesday, January 9th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $107.75.

Institutional Trading of Plexus

Several institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC boosted its stake in Plexus by 7.4% in the 1st quarter. ProShare Advisors LLC now owns 5,540 shares of the technology company’s stock valued at $525,000 after purchasing an additional 383 shares during the period. Isthmus Partners LLC raised its holdings in Plexus by 37.1% in the 1st quarter. Isthmus Partners LLC now owns 35,522 shares of the technology company’s stock valued at $3,368,000 after acquiring an additional 9,605 shares in the last quarter. Inspire Investing LLC raised its holdings in Plexus by 6.7% in the 1st quarter. Inspire Investing LLC now owns 3,803 shares of the technology company’s stock valued at $361,000 after acquiring an additional 238 shares in the last quarter. SG Americas Securities LLC acquired a new position in Plexus in the 1st quarter valued at $253,000. Finally, Quantbot Technologies LP acquired a new position in Plexus in the 1st quarter valued at $533,000. 94.45% of the stock is currently owned by institutional investors.

Plexus Company Profile

Plexus Corp. provides electronic manufacturing services in the United States and internationally. It offers design, develop, supply chain, new product introduction, and manufacturing solutions, as well as sustaining services to companies in the healthcare/life sciences, industrial/commercial, aerospace/defense, and communications market sectors.